These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28638795)

  • 1. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma.
    Agrawal S
    World J Clin Oncol; 2017 Jun; 8(3):255-260. PubMed ID: 28638795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas.
    Hayakawa H; Fukasawa M; Sato T; Takano S; Kadokura M; Shindo H; Takahashi E; Hirose S; Kawakami S; Fukasawa Y; Maekawa S; Inoue T; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Mochizuki K; Kondo T; Ichikawa D; Enomoto N
    J Gastroenterol; 2019 Nov; 54(11):1029-1037. PubMed ID: 31111221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in pancreatic adenocarcinoma: current perspectives.
    Swords DS; Firpo MA; Scaife CL; Mulvihill SJ
    Onco Targets Ther; 2016; 9():7459-7467. PubMed ID: 28003762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma.
    Li X; Li S; Liu L; Hong J; Zhao T; Gao C
    J Cancer; 2020; 11(1):9-15. PubMed ID: 31892968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort.
    Zhou G; Liu X; Wang X; Jin D; Chen Y; Li G; Li C; Fu D; Xu W; Wang X
    Onco Targets Ther; 2017; 10():1199-1206. PubMed ID: 28280354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
    Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
    Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.
    Ballehaninna UK; Chamberlain RS
    Indian J Surg Oncol; 2011 Jun; 2(2):88-100. PubMed ID: 22693400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
    Karásek P; Hermanová M
    Klin Onkol; 2016; 29(5):336-341. PubMed ID: 27739311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
    Chang JC; Kundranda M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of carcinoembryonic antigen levels and cytology of pure pancreatic juice in diagnosis of pancreatic cancer.
    Tatsuta M; Yamamura H; Yamamoto R; Okano Y; Morii T; Okuda S; Tamura H
    Cancer; 1983 Nov; 52(10):1880-5. PubMed ID: 6627206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.